Yeramian Patrick D 的 Form 4/A 修正申報

修正

Amylyx Pharmaceuticals, Inc.（AMLX），2023/3/24 申報

申報編號: 0000899243-23-009600
申報時間: 2023/3/24 18:45 ET
交易日: 2023/3/16
申報延遲: 8 天
10b5-1 計畫: 沒有勾選
原始申報日: 2023/3/20

SEC EDGAR 原文（在新分頁開啟）

這份申報列了 6 筆非衍生性交易、4 筆衍生性交易。公開市場賣出合計 $174.1 萬。交易後 8 天申報。

這份修正申報取代了 0000899243-23-009178（2023/3/20 申報）。

申報人

一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人	與公司的關係
Yeramian Patrick DCIK 0001358266	高階主管（醫療長）

非衍生性證券（表 I）

普通股等股票的取得與處分，每一列是申報上的一筆。

非衍生性證券的交易
交易日	證券	交易	股數	價格	金額	交易後持股	持有方式
2023/3/16	Common Stock	M行使選擇權取得	+2,789	$0.33	+$920.37	207,088	直接
2023/3/16	Common Stock	M行使選擇權取得	+30,041	$0.37	+$11,115.17	237,129	直接
2023/3/16	Common Stock	M行使選擇權取得	+16,748	$6.88	+$115,226.24	253,877	直接
2023/3/16	Common Stock	S賣出處分	−52,211	$31.85^F3	−$1,662,842.03	201,666	直接
2023/3/16	Common Stock	S賣出處分	−2,416	$32.43^F4	−$78,358.37	199,250	直接
2023/3/16	Common Stock	A公司授予取得	+9,167	$0.00	$0	208,417	直接

衍生性證券（表 II）

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日	證券	交易	標的股數	單價	金額	交易後持有	持有方式
2023/3/16	Common Stock	A公司授予取得	+41,250	$0.00	$0	41,250	直接
2023/3/16	Common Stock	M行使選擇權處分	−2,789	$0.00	$0	0	直接
2023/3/16	Common Stock	M行使選擇權處分	−30,041	$0.00	$0	62,466	直接
2023/3/16	Common Stock	M行使選擇權處分	−16,748	$0.00	$0	48,252	直接

附註與備註

本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。

On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

表 I 有 1 筆交易的價格引用這則附註。

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

表 I 有 1 筆交易的價格引用這則附註。

The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

The shares subject to such option are vested and currently exercisable.

As of the date of this filing, 39,688 shares subject to the option are vested and exercisable. 52,819 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.

16,256 shares underlying this option vested on February 19, 2022, with the remaining shares vesting in monthly installments of 1,354 shares thereafter.

備註

Exhibit List: Exhibit 24. This Power of Attorney was inadvertently omitted from the Form 3 filed on January 6, 2022.

看 SEC EDGAR 上的完整原文（在新分頁開啟）